Your browser doesn't support javascript.
loading
Current pharmacotherapy of overactive bladder
Kreydin, Evgenyi I; Gomes, Cristiano M; Cruz, Francisco.
Affiliation
  • Kreydin, Evgenyi I; University of Southern California. Keck School of Medicine. Department of Urology. Los Angeles. US
  • Gomes, Cristiano M; Faculdade de Medicina da Universidade de São Paulo. Departamento de Cirurgia. Divisão de Urologia. São Paulo. BR
  • Cruz, Francisco; Faculdade de Medicina do Porto. Hospital de S. João. Departamento de Urologia. Porto. PT
Int. braz. j. urol ; 47(6): 1091-1107, Nov.-Dec. 2021. tab
Article in En | LILACS | ID: biblio-1340029
Responsible library: BR1.1
ABSTRACT
ABSTRACT Overactive bladder is a symptom complex consisting of bothersome storage urinary symptoms that is highly prevalent among both sexes and has a significant impact on quality of life. Various antimuscarinic agents and the beta-3 agonists mirabegron and vibegron are currently available for the treatment of OAB. Each drug has specific pharmacologic properties, dosing schedule and tolerability profile, making it essential to individualize the medical treatment for the patient's characteristics and expectations. In this manuscript, we review the most important factors involved in the contemporary pharmacological treatment of OAB.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: 1 Index: LILACS Main subject: Urinary Bladder, Overactive Limits: Female / Humans / Male Language: En Journal: Int. braz. j. urol Journal subject: UROLOGIA Year: 2021 Type: Article
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: 1 Index: LILACS Main subject: Urinary Bladder, Overactive Limits: Female / Humans / Male Language: En Journal: Int. braz. j. urol Journal subject: UROLOGIA Year: 2021 Type: Article